Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$41.10 USD

41.10
1,352,083

-0.08 (-0.19%)

Updated Aug 14, 2024 02:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Merck's (MRK) Pneumococcal Vaccine Succeeds in Pediatric Trials

Merck's (MRK) 15-valent pneumococcal conjugate vaccine candidate, V114, demonstrates comparable immunogenicity and safety compared to a lower valency vaccine in infants and children.

Kinjel Shah headshot

Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal

Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints

The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology

The Zacks Analyst Blog Highlights: GlaxoSmithKline, Sanofi, CureVac and Vir Biotechnology

Sanofi (SNY) to Start Phase III COVID-19 Vaccine Study Soon

Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the coming weeks.

Glaxo/Medicago COVID-19 Vaccine Shows Strong Immune Response

Glaxo (GSK) and its partner Medicago's adjuvant COVID-19 vaccine candidate induces robust neutralizing antibody and cellular immune responses in mid-stage study participants.

Novavax's (NVAX) Q1 Loss Widens, Revenues Beat, Shares Down

Novavax (NVAX) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Shares fall in after-hours trading.

Theravance (TBPH) Q1 Earnings Lag Estimates, Pipeline on Track

Theravance's (TBPH) loss narrows in the first quarter of 2021 while revenues decline year over year.

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson

Kinjel Shah headshot

Pharma Stock Roundup: Big Drugmakers' Q1 Earnings, Resumption of JNJ US COVID-19 Jabs

Several large drugmakers announce Q1 earnings. Many miss estimates for both earnings and sales. J&J (JNJ) resumes COVID-19 vaccination in the United States.

Gilead (GILD) Beats on Q1 Earnings, HIV Sales Decline

Gilead (GILD) reports mixed results for the first quarter as the ongoing pandemic adversely impacted core HIV segment sales.

Seagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.

Glaxo's (GSK) Q1 Earnings In Line, Sales Hit by COVID-19

Glaxo's (GSK) revenues get hurt by disruption related to COVID-19 pandemic. However, robust growth in respiratory, immuno-inflammation and cancer drugs partially offset the decline.

Sanofi (SNY) Q1 Earnings & Sales Beat, Keeps 2021 EPS View

Sanofi's (SNY) Q1 earnings and sales beat estimates. Dupixent drives sales growth in the quarter.

Glaxo (GSK) Miss Earnings and Revenues Estimates in Q1

Glaxo miss earnings as well as revenues estimates in the first quarter of 2021. Stock down.

Is a Beat Likely for AstraZeneca (AZN) in Q1 Earnings?

AstraZeneca's (AZN) first-quarter results are expected to reflect the impact of strong demand for new drugs as well as coronavirus-led disruption. Investors are likely to focus on COVID-19 vaccine related updates.

Eli Lilly (LLY) Q1 Earnings Miss, COVID-19 Drug Demand Low

Lilly (LLY) misses first-quarter estimates for both earnings and sales. It narrows 2021 forecast. Stock down in pre-market trading.

Should You Buy GlaxoSmithKline (GSK) Ahead of Earnings?

GlaxoSmithKline (GSK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Glaxo (GSK) Gets FDA Nod for Endometrial Cancer Drug Jemperli

The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating women with recurrent or advanced dMMR endometrial cancer.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates

J&J (JNJ) beats Q1 estimates for earnings and sales. Roche (RHHBY) announces Q1 sales numbers.

What's in the Cards for Eli Lilly (LLY) This Earnings Season?

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) first-quarter sales.

Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU

The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's COVID-19 Vaccine Woes, MRK Ends COVID-19 Drug Development

FDA & CDC temporarily halt J&J's (JNJ) COVID-19 vaccine use. Merck (MRK) ends development of COVID-19 drug.

Will Solid Pharma Unit Performance Drive J&J (JNJ) Q1 Earnings?

In J&J's (JNJ) Pharma segment, its oncology drugs, Imbruvica and Darzalex as well as psoriasis treatment drug, Stelara, are likely to have driven sales growth.

Regeneron (REGN) Posts Positive Data on COVID-19 Antibody Cocktail

Regeneron (REGN) announces encouraging data on antibody cocktail, REGEN-COV, from two phase III studies.

Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data (Revised)

Dynavax's (DVAX) partner Valneva, developing a COVID-19 vaccine using Dynavax's adjuvant, reports 100% seroconversion rates from a phase I/II study.